Daniil Gataulin

Stock Analyst at Chardan Capital

(0.89)
# 2285
Out of 5,383 analysts
101
Total ratings
Success rate
Average return
Main Sectors:
Top Industries:
19 Stocks
Name Action PT Current % Upside Ratings Updated
OCGN Ocugen
Maintains: Buy
7 7
1.02 586.27% 12 Jun 24, 2025
FBRX Forte Biosciences
Maintains: Buy
61 61
11.35 437.44% 5 Jun 24, 2025
RGNX Regenxbio
Maintains: Buy
52 52
8.78 492.26% 11 Jun 9, 2025
QURE uniQure
Maintains: Buy
38 38
14.23 167.04% 4 May 30, 2025
ADVM Adverum Biotechnolog...
Maintains: Buy
33 33
2.48 1230.65% 7 May 15, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
38 35
6.67 424.74% 4 May 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
14 15
7.1 111.27% 6 May 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
28 33
19.47 69.49% 7 May 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
33 27
10.41 159.37% 11 May 8, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
8 4
n/a n/a 7 May 8, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
70 70
16.7 319.16% 2 May 5, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
4 4
0.79 406.33% 4 Apr 23, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
6 6
0.81 640.74% 4 Mar 28, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
3 3
1.75 71.43% 8 Feb 18, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
220 220
n/a n/a 1 Mar 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Jul 25, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Feb 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
22 13
n/a n/a 2 Nov 8, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
5 3
n/a n/a 2 Sep 28, 2022